PDUFA Dates: April 2027

1 FDA target action date in April 2027. Each PDUFA date is the FDA's deadline to complete review of a drug application.

A single FDA target action date this month — ozekibart (INBRX-109) from Inhibrx Biosciences, Inc for Unresectable/metastatic conventional chondrosarcoma.